Skip to main content

SOP on Clinical Trial Monitoring Procedure

 Title: Clinical Trial Monitoring Procedure

Introduction and Purpose:

The purpose of this Standard Operating Procedure (SOP) is to outline the requirements for conducting interventional clinical trials at the clinical site It serves as a guide to promote quality and ensure adherence to Good Clinical Practice (GCP) standards. This SOP may also be applied to other types of clinical research studies to maintain high standards of quality.

Scope:

This SOP applies to all personnel involved in the monitoring of ESCTs, including clinical monitors, site coordinators, investigators, and other relevant staff.

Definitions and Acronyms:

  • Clinical Research: Encompasses all research involving human participants, excluding secondary studies using existing biological specimens or data collected without identifiers or publicly available data.
  • Clinical Trial: Refers to clinical research studies involving human participants assigned to an intervention designed to evaluate the effect(s) of the intervention on the participant and the effect being evaluated is a health-related biomedical or behavioral outcome.
  • CFR: Code of Federal Regulations
  • CRO: Contract Research Organization
  • EHR: Electronic Health Record
  • ERICA: Electronic Research Integrity and Compliance Administration
  • FDA: United States Food and Drug Administration
  • GCP: Good Clinical Practice
  • ICF: Informed Consent Form
  • ICH: International Council for Harmonization
  • IDS: Investigational Drug Services
  • IRB: Institutional Review Board
  • LAR: Legally Authorized Representative
  • PI: Principal Investigator
  • SOP: Standard Operating Procedure

Procedure:

Monitoring Expectations:

  • Monitoring will be performed as per the sponsor's requirements and should be scheduled based on the trial's complexity and risk.
  • Monitoring may involve on-site and/or central/remote monitoring to ensure the proper conduct and documentation of the trial.
  • The monitor's responsibilities include overseeing the trial, ensuring proper documentation, and facilitating communication between the sponsor and the investigator.

Scheduling On-Site Monitoring Visits:

  • Assigned monitors are expected to schedule monitoring visits with advance notice.
  • Monitors can visit for a mutually agreed-upon number of consecutive days per month for each protocol. The expected duration should be communicated to the study team.
  • Scheduling should consider space availability and potential exceptions for accommodating multiple studies in one visit.

Monitoring Visit Preparation:

  • The study team should identify mutually available dates, reserve necessary space, and schedule meetings with required parties.
  • Notification of the upcoming monitoring visit should be sent to potentially affected individuals.
  • The study team should prepare requested documentation, organize research charts, obtain and file any missing source documentation, and ensure data and case report forms (CRFs) are complete.
  • All essential documents should be filed, and training and delegation logs should be up-to-date.

On-Site Monitoring Visit Expectations:

  • Upon arrival, the monitor should notify the study team and sign in.
  • The study team should familiarize the monitor with their surroundings.
  • Monitors may share space with other site monitors.
  • Monitors should exhibit professional and ethical behavior.
  • Review of study materials should align with the initially requested items during the monitoring site visit setup.
  • Monitors won't have unrestricted access to the Electronic Health Record (EHR) but may have limited access as needed.
  • Monitors should not enter secured areas without authorized personnel.
  • All provided materials for review should be returned at the end of each business day.
  • Monitors are not allowed to duplicate research records.

Monitor Visit Follow-up:

  • The monitor should provide a summary of their review in a monitoring report and/or follow-up letter to the PI.
  • The PI and study team should address findings, data queries, and implement corrective actions.
  • The monitoring visit report should be maintained with other essential study documents.

Centralized/Remote Monitoring:

  • Centralized and remote monitoring can reduce on-site monitoring.
  • Limited remote monitoring may be possible from the clinical site EHR.
  • Regulatory records and IDS records may also be available for remote monitoring.
  • Requests for centralized/remote monitoring must be approved in advance.

Additional Considerations:

  • The monitor should schedule close-out monitoring visits as needed.
  • Any changes to sponsor-assigned monitoring personnel should be communicated to the study team.

Materials Required:

  • Current IRB approved protocol/amendment(s)
  • Current IRB Approved Consent Form(s)
  • Participant research charts
  • Access to electronic data capture (EDC) system
  • Access to essential documents / regulatory binders
  • Access to Vestigo

References:

  • 21 CFR Part 50 Subpart B: Protection of Human Subjects
  • 21 CFR Part 312 Subpart D – Investigational New Drug Application, Responsibilities of Sponsors and Investigators
  • ICH Guidance for Industry E6(R2): Good Clinical Practice

Document Approval:

Labels:

Popular posts from this blog

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases often r
Read more

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such as ho
Read more

SOP on Investigational New Drug (IND) Application and Clinical Investigation Policy

Title: Investigational New Drug (IND) Application and Clinical Investigation Policy Introduction and Purpose: The conduct of clinical investigations (clinical trials) under an FDA-Regulated Investigational New Drug (IND) application involves compliance with a complex set of FDA regulations, requirements, and responsibilities. The FDA holds the IND application sponsor accountable for ensuring compliance with these regulations (21 CFR Part 312, Subpart D). While pharmaceutical companies are typical IND sponsors, individuals, governmental agencies, and academic institutions may also serve as sponsors (21 CFR Part 312.3). This policy serves the following purposes: To assist in determining when an IND is necessary. To provide guidance and resources for individuals conducting clinical investigations, including sponsor-investigators, on obtaining an IND for the investigational drug. To outline the process for compassionate use (expanded access) and emergency use of investigational drugs. Defi
Read more

Engineering AAV vectors for enhanced safety profiles

 Engineering AAV vectors for enhanced safety profiles involves multiple strategies at both the vector genome and capsid levels. Here is a breakdown of these strategies: Vector Genome Level: Modifying Vector Genome Sequences: Scientists modify AAV vector genomes by adding, mutating, or deleting specific sequences. For example, self-complementary AAV (scAAV) vectors are designed by deleting key signals from the second inverted terminal repeat (ITR), allowing for more efficient genome replication. Codon Optimization: Optimizing the codon usage of the transgene can enhance its expression efficiency. Promoter and PolyA Sequence Selection: Careful selection and manipulation of promoter and polyadenylation (polyA) sequences can influence transgene expression and tissue specificity. Capsid Engineering: Capsid engineering strategies can be categorized into four main categories: Directed Evolution: This approach involves creating capsid mutant libraries using error-prone PCR or introducing pepti
Read more

SOP on Safety Events Reporting In Clinical Trials

Title: Standard Operating Procedure for Collection, Evaluation, Documentation, and Reporting of Safety Events in Clinical Trials Introduction and Purpose The assessment of safety events and the accurate reporting of these events are fundamental aspects of conducting clinical trials. These processes are crucial for ensuring the safety and well-being of research participants. This Standard Operating Procedure (SOP) outlines the procedures for collecting, evaluating, documenting, and reporting safety events, including Adverse Events (AE), Serious Adverse Events (SAE), Unanticipated Problems (UP), and other relevant safety events during the course of a clinical trial. The Principal Investigator (PI) holds the primary responsibility for the overall conduct of the trial, safeguarding the rights, safety, and welfare of study subjects, and ensuring that the investigation adheres to the protocol, Good Clinical Practice (GCP), Institutional Review Board (IRB), Food and Drug Administration (FDA),
Read more